Catalog / epsilogen.com

SEO audit for epsilogen.com

Home - Epsilogen

otherWordPress

Health 65/100 (fair) · 50 pages crawled · generated 2026-08-26

Download Markdown report (feed to ChatGPT / Claude / Cursor)

pages crawled

indexable pages

errors

160

warnings

426

notices

orphan pages

broken links

Category breakdown

Category	Score	Warnings	Notices
Agent Readiness	70	50	5
Performance	70	50	115
Titles	82	30	0
Structured Data	88	20	71
Duplicate	97	5	2
Meta Description	98	4	34
Headings	99	1	2
Content	100	0	50
Images	100	0	7
Links	100	0	4
Security	100	0	100
Social	100	0	27
URL	100	0	9

Findings

Warnings (8 rules)

warning Control has no accessible name

Rule agent.control_no_name · Agent Readiness · 50 occurrence(s)

https://epsilogen.com/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/aacr-virtual-annual-meeting/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — 2 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/epsilogen-licences-mov18-ige/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/genetic-engineering-news-article/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/igem-announces-funding-ige-antibody/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/iontas-and-igem-collaborate/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — 1 button/link(s) with no text or aria-label — an agent can't target them
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — 1 button/link(s) with no text or aria-label — an agent can't target them

warning Near-duplicate page content

Rule duplicate.near · Duplicate · 5 occurrence(s)

https://epsilogen.com/biocentury/ — near-duplicate of 2 page(s): https://epsilogen.com/episologen-lonza-manufacture-first-ige-to-treat-ovarian-cancer/, https://epsilogen.com/esgo-2025-mov18-eposter/
https://epsilogen.com/episologen-lonza-manufacture-first-ige-to-treat-ovarian-cancer/ — near-duplicate of 2 page(s): https://epsilogen.com/biocentury/, https://epsilogen.com/esgo-2025-mov18-eposter/
https://epsilogen.com/esgo-2025-mov18-eposter/ — near-duplicate of 2 page(s): https://epsilogen.com/episologen-lonza-manufacture-first-ige-to-treat-ovarian-cancer/, https://epsilogen.com/biocentury/
https://epsilogen.com/her2-ige/ — near-duplicate of 1 page(s): https://epsilogen.com/igees/
https://epsilogen.com/igees/ — near-duplicate of 1 page(s): https://epsilogen.com/her2-ige/

warning Missing <h1>

Rule h1.missing · Headings · 1 occurrence(s)

https://epsilogen.com/esgo-2025-mov18-eposter/

warning Missing meta description

Rule meta_desc.missing · Meta Description · 4 occurrence(s)

warning Render-blocking script in <head> (no defer/async)

Rule perf.render_blocking · Performance · 50 occurrence(s)

https://epsilogen.com/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/aacr-virtual-annual-meeting/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/epsilogen-licences-mov18-ige/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/genetic-engineering-news-article/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/igem-announces-funding-ige-antibody/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/iontas-and-igem-collaborate/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — 2 render-blocking <script> in <head> (add defer/async or use type=module)

warning BreadcrumbList present but structurally incomplete

Rule schema.breadcrumb_incomplete · Structured Data · 1 occurrence(s)

https://epsilogen.com/ — a BreadcrumbList is present but structurally incomplete — missing required itemListElement. Give itemListElement at least 2 ListItems, each with a sequential integer position and a name, and an item URL on every entry except the last.

warning Schema describes content not visible on the page

Rule schema.hidden_content · Structured Data · 19 occurrence(s)

https://epsilogen.com/ — a schema name/headline ("Home - Epsilogen") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/2023-cancer-research-highlights-drug-development-at-its-best/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/anti-cancer-pro-inflammatory-effects-of-an-ige-antibody-targeting-the-melanomaassociated-antigen-chondroitin-sulfate-proteoglycan-4/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/arpa-h-backs-advancement-of-engineered-iga-antibody-therapeutics-toward-clinical-development/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/elucidating-the-relationship-between-affinity-and-potency-in-the-performance-of-therapeutic-ige/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/episologen-lonza-manufacture-first-ige-to-treat-ovarian-cancer/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/epsilogen-acquires-tigatx-to-expand-its-antibody-arsenal/ — a schema name/headline ("Jaime Swart") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/epsilogen-announces-acquisition-of-tigatx-inc-to-create-worlds-leading-pan-isotype-cancer-antibody-company/ — a schema name/headline ("Jaime Swart") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/epsilogen-announces-initiation-of-phase-ib-trial-of-mov18-ige/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/epsilogen-announces-the-appointment-of-cristina-oliva-md-phd-as-chief-medical-officer/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/how-cruks-biotech-like-group-is-accelerating-clinical-development-for-industry-partners/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/mov18-opening-a-new-front-for-immunotherapy/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/nature-highlights-ige-cancer-antibodies-as-a-promising-new-technology-to-watch-in-2021/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/safety-and-anti-tumour-activity-of-the-ige-antibody-mov18-in-patients-with-advanced-solid-tumours-expressing-folate-receptor-alpha-a-phase-i-trial/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.
https://epsilogen.com/the-life-sciences-future50/ — a schema name/headline ("Krishna Thapa") does not appear in the page's visible text — Google's policies prohibit marking up content not visible to readers. This is a heuristic (a static-HTML substring check): JS-rendered or abbreviated names can be false positives, so verify before removing.

warning Title likely truncated in SERP (too wide)

Rule title.too_long · Titles · 30 occurrence(s)

https://epsilogen.com/aacr-virtual-annual-meeting/ — 179 chars, ~1374px (limit ~580px)
https://epsilogen.com/anti-cancer-pro-inflammatory-effects-of-an-ige-antibody-targeting-the-melanomaassociated-antigen-chondroitin-sulfate-proteoglycan-4/ — 143 chars, ~1089px (limit ~580px)
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — 132 chars, ~1073px (limit ~580px)
https://epsilogen.com/epsilogen-announces-acquisition-of-tigatx-inc-to-create-worlds-leading-pan-isotype-cancer-antibody-company/ — 121 chars, ~959px (limit ~580px)
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — 111 chars, ~841px (limit ~580px)
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — 113 chars, ~871px (limit ~580px)
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — 134 chars, ~1042px (limit ~580px)
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — 100 chars, ~783px (limit ~580px)
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — 177 chars, ~1318px (limit ~580px)
https://epsilogen.com/epsilogen-licences-mov18-ige/ — 111 chars, ~856px (limit ~580px)
https://epsilogen.com/epsilogen-raises-30m-series-b-bioworld/ — 110 chars, ~832px (limit ~580px)
https://epsilogen.com/how-cruks-biotech-like-group-is-accelerating-clinical-development-for-industry-partners/ — 100 chars, ~762px (limit ~580px)
https://epsilogen.com/igem-announces-funding-ige-antibody/ — 117 chars, ~918px (limit ~580px)
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — 90 chars, ~688px (limit ~580px)
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — 139 chars, ~1093px (limit ~580px)
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — 94 chars, ~719px (limit ~580px)
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — 84 chars, ~675px (limit ~580px)
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — 92 chars, ~757px (limit ~580px)
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — 77 chars, ~609px (limit ~580px)
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — 196 chars, ~1486px (limit ~580px)
https://epsilogen.com/iontas-and-igem-collaborate/ — 96 chars, ~722px (limit ~580px)
https://epsilogen.com/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech/ — 119 chars, ~875px (limit ~580px)
https://epsilogen.com/safety-and-anti-tumour-activity-of-the-ige-antibody-mov18-in-patients-with-advanced-solid-tumours-expressing-folate-receptor-alpha-a-phase-i-trial/ — 159 chars, ~1189px (limit ~580px)
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — 127 chars, ~980px (limit ~580px)
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — 90 chars, ~702px (limit ~580px)

Notices (18 rules)

notice Heading levels skip a level

Rule agent.heading_skip · Agent Readiness · 4 occurrence(s)

https://epsilogen.com/board-of-directors/ — h3 follows h1 — skips h2
https://epsilogen.com/epsilogen-announces-acquisition-of-tigatx-inc-to-create-worlds-leading-pan-isotype-cancer-antibody-company/ — h3 follows h1 — skips h2
https://epsilogen.com/genetic-engineering-news-article/ — h3 follows h1 — skips h2
https://epsilogen.com/management-team/ — h3 follows h1 — skips h2

notice No llms.txt for AI agents

Rule agent.llms_txt_missing · Agent Readiness · 1 occurrence(s)

https://epsilogen.com/ — no llms.txt found at the site root — add one so AI agents get a curated site summary

notice Main text is hard to read (low Flesch Reading Ease)

Rule content.readability_poor · Content · 50 occurrence(s)

https://epsilogen.com/ — this page reads as very difficult (Flesch Reading Ease 28, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — this page reads as very difficult (Flesch Reading Ease 28, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/aacr-virtual-annual-meeting/ — this page reads as difficult (Flesch Reading Ease 37, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — this page reads as very difficult (Flesch Reading Ease 24, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — this page reads as very difficult (Flesch Reading Ease 29, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — this page reads as very difficult (Flesch Reading Ease 27, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — this page reads as very difficult (Flesch Reading Ease 25, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — this page reads as difficult (Flesch Reading Ease 35, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — this page reads as very difficult (Flesch Reading Ease 24, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — this page reads as very difficult (Flesch Reading Ease 26, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — this page reads as difficult (Flesch Reading Ease 33, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/epsilogen-licences-mov18-ige/ — this page reads as difficult (Flesch Reading Ease 32, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/genetic-engineering-news-article/ — this page reads as difficult (Flesch Reading Ease 40, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/igem-announces-funding-ige-antibody/ — this page reads as very difficult (Flesch Reading Ease 28, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — this page reads as very difficult (Flesch Reading Ease 17, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — this page reads as very difficult (Flesch Reading Ease 27, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — this page reads as very difficult (Flesch Reading Ease 30, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — this page reads as difficult (Flesch Reading Ease 30, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — this page reads as very difficult (Flesch Reading Ease 29, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — this page reads as difficult (Flesch Reading Ease 40, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — this page reads as difficult (Flesch Reading Ease 39, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/iontas-and-igem-collaborate/ — this page reads as very difficult (Flesch Reading Ease 19, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — this page reads as difficult (Flesch Reading Ease 40, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — this page reads as difficult (Flesch Reading Ease 31, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — this page reads as difficult (Flesch Reading Ease 36, below 50) — long sentences and multi-syllable words make it hard to scan. Shorten sentences and prefer plainer words to widen your audience. Density can be legitimate for expert, technical or legal content, so judge it against who the page is for.

notice Duplicate meta description across pages

Rule duplicate.meta_desc · Duplicate · 2 occurrence(s)

https://epsilogen.com/her2-ige/ — meta description shared by 2 pages: https://epsilogen.com/igees/
https://epsilogen.com/igees/ — meta description shared by 2 pages: https://epsilogen.com/her2-ige/

notice Multiple <h1> elements

Rule h1.multiple · Headings · 2 occurrence(s)

https://epsilogen.com/board-of-directors/ — 7 <h1> elements
https://epsilogen.com/management-team/ — 8 <h1> elements

notice Image filename is generic/auto-generated (missed image-search signal)

Rule images.generic_filename · Images · 3 occurrence(s)

https://epsilogen.com/ — 1 image(s) use a generic/auto-generated filename (e.g. IMG_1234.jpg, photo1.png, a bare UUID). Google reads the filename as a signal of image content, so rename files descriptively (hyphen-separated words) before upload.
https://epsilogen.com/2023-cancer-research-highlights-drug-development-at-its-best/ — 1 image(s) use a generic/auto-generated filename (e.g. IMG_1234.jpg, photo1.png, a bare UUID). Google reads the filename as a signal of image content, so rename files descriptively (hyphen-separated words) before upload.
https://epsilogen.com/epsilogens-ceo-speaks-lu-rahman/ — 1 image(s) use a generic/auto-generated filename (e.g. IMG_1234.jpg, photo1.png, a bare UUID). Google reads the filename as a signal of image content, so rename files descriptively (hyphen-separated words) before upload.

notice Likely hero image lacks fetchpriority=high

Rule images.hero_no_fetchpriority · Performance · 46 occurrence(s)

https://epsilogen.com/ — the likely hero/LCP image (epsoligen-bg.jpg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/aacr-virtual-annual-meeting/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/epsilogen-licences-mov18-ige/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/genetic-engineering-news-article/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/igem-announces-funding-ige-antibody/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — the likely hero/LCP image (best-start-up-biotech-company-igem-therapeutics.jpg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/iontas-and-igem-collaborate/ — the likely hero/LCP image (iontas-igem-collaborate.jpg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — the likely hero/LCP image (logo.svg) has no fetchpriority="high" — adding it tells the browser to fetch the hero earlier in the waterfall, reducing Largest Contentful Paint. This is a low-severity nudge; verify the flagged image is actually your LCP element.

notice Images without width/height (layout shift / CLS)

Rule images.missing_dimensions · Images · 4 occurrence(s)

https://epsilogen.com/ — 4 of 12 images without width/height
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — 1 of 4 images without width/height
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — 1 of 4 images without width/height
https://epsilogen.com/iontas-and-igem-collaborate/ — 1 of 6 images without width/height

notice Internal link has no anchor text / accessible name

Rule links.no_anchor_text · Links · 4 occurrence(s)

https://epsilogen.com/biocentury/ — 1 internal link(s) have no anchor text, aria-label, or image alt — they pass no keyword signal and are unusable to screen readers. Add descriptive text or an aria-label.
https://epsilogen.com/board-of-directors/ — 4 internal link(s) have no anchor text, aria-label, or image alt — they pass no keyword signal and are unusable to screen readers. Add descriptive text or an aria-label.
https://epsilogen.com/epsilogen-acquires-tigatx-to-expand-its-antibody-arsenal/ — 1 internal link(s) have no anchor text, aria-label, or image alt — they pass no keyword signal and are unusable to screen readers. Add descriptive text or an aria-label.
https://epsilogen.com/management-team/ — 4 internal link(s) have no anchor text, aria-label, or image alt — they pass no keyword signal and are unusable to screen readers. Add descriptive text or an aria-label.

notice Meta description too long

Rule meta_desc.too_long · Meta Description · 34 occurrence(s)

notice Missing Open Graph tags

Rule og.missing · Social · 27 occurrence(s)

https://epsilogen.com/ — og:description
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — og:image
https://epsilogen.com/aacr-virtual-annual-meeting/ — og:image
https://epsilogen.com/apply-for-a-job/ — og:description, og:image
https://epsilogen.com/arpa-h-backs-advancement-of-engineered-iga-antibody-therapeutics-toward-clinical-development/ — og:image
https://epsilogen.com/elucidating-the-relationship-between-affinity-and-potency-in-the-performance-of-therapeutic-ige/ — og:image
https://epsilogen.com/epsilogen-announces-acquisition-of-tigatx-inc-to-create-worlds-leading-pan-isotype-cancer-antibody-company/ — og:image
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — og:image
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — og:image
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — og:image
https://epsilogen.com/epsilogen-announces-the-appointment-of-cristina-oliva-md-phd-as-chief-medical-officer/ — og:image
https://epsilogen.com/epsilogen-licences-mov18-ige/ — og:image
https://epsilogen.com/genetic-engineering-news-article/ — og:image
https://epsilogen.com/her2-ige/ — og:image
https://epsilogen.com/igem-announces-funding-ige-antibody/ — og:image
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — og:image
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — og:image
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — og:image
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — og:image
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — og:image
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — og:image
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — og:image
https://epsilogen.com/scientific-founder/ — og:description, og:image
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — og:image
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — og:image

notice Legacy image format (jpg/png/gif) with no next-gen fallback

Rule perf.images_legacy_format · Performance · 19 occurrence(s)

https://epsilogen.com/ — 9 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/2023-cancer-research-highlights-drug-development-at-its-best/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/anti-cancer-pro-inflammatory-effects-of-an-ige-antibody-targeting-the-melanomaassociated-antigen-chondroitin-sulfate-proteoglycan-4/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/biocentury/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/board-of-directors/ — 16 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/episologen-lonza-manufacture-first-ige-to-treat-ovarian-cancer/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/epsilogen-raises-30m-series-b-bioworld/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/epsilogens-ceo-speaks-lu-rahman/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/her2-ige/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/how-cruks-biotech-like-group-is-accelerating-clinical-development-for-industry-partners/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/igees/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/iontas-and-igem-collaborate/ — 3 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/management-team/ — 18 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/mov18-opening-a-new-front-for-immunotherapy/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/nature-highlights-ige-cancer-antibodies-as-a-promising-new-technology-to-watch-in-2021/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/safety-and-anti-tumour-activity-of-the-ige-antibody-mov18-in-patients-with-advanced-solid-tumours-expressing-folate-receptor-alpha-a-phase-i-trial/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.
https://epsilogen.com/the-life-sciences-future50/ — 1 image(s) use a legacy format (jpg/png/gif) with no next-gen <picture> fallback. Serve WebP or AVIF (with a <picture> typed <source>) to cut image transfer weight and improve LCP.

notice No ETag header (no conditional GET for unchanged pages)

Rule perf.no_etag · Performance · 50 occurrence(s)

https://epsilogen.com/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/aacr-virtual-annual-meeting/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/epsilogen-licences-mov18-ige/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/genetic-engineering-news-article/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/igem-announces-funding-ige-antibody/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/iontas-and-igem-collaborate/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — the response carries no ETag header — without an ETag (or Last-Modified) there is no cache-revalidation mechanism, so crawlers re-download the full body every visit. Emit an ETag (a content hash) to enable conditional If-None-Match requests.

notice Article schema missing recommended properties (Top Stories / image carousel)

Rule schema.article_incomplete · Structured Data · 21 occurrence(s)

https://epsilogen.com/2-million-raised-from-epidarex-capital/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/aacr-virtual-annual-meeting/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/arpa-h-backs-advancement-of-engineered-iga-antibody-therapeutics-toward-clinical-development/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/elucidating-the-relationship-between-affinity-and-potency-in-the-performance-of-therapeutic-ige/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/epsilogen-announces-acquisition-of-tigatx-inc-to-create-worlds-leading-pan-isotype-cancer-antibody-company/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/epsilogen-announces-the-appointment-of-cristina-oliva-md-phd-as-chief-medical-officer/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/epsilogen-licences-mov18-ige/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/genetic-engineering-news-article/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/igem-announces-funding-ige-antibody/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — Article structured data is missing recommended property (image) — these feed Top Stories and image-carousel eligibility. Google defines no required Article properties, so this is advisory: add author, headline, image and datePublished where they apply.

notice Deprecated schema type with no Google rich result

Rule schema.deprecated_type · Structured Data · 50 occurrence(s)

https://epsilogen.com/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/aacr-virtual-annual-meeting/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/epsilogen-licences-mov18-ige/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/genetic-engineering-news-article/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/igem-announces-funding-ige-antibody/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/iontas-and-igem-collaborate/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — deprecated rich-result type(s) present: Sitelinks Searchbox. The markup is valid schema.org but Google no longer generates a rich result for it — remove or repurpose the block.

notice Missing recommended security headers

Rule security.missing_headers · Security · 50 occurrence(s)

https://epsilogen.com/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/aacr-virtual-annual-meeting/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — X-Content-Type-Options, HSTS, CSP
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — X-Content-Type-Options, HSTS, CSP
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — CSP, X-Content-Type-Options, HSTS
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/epsilogen-licences-mov18-ige/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/genetic-engineering-news-article/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/igem-announces-funding-ige-antibody/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — CSP, X-Content-Type-Options, HSTS
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/iontas-and-igem-collaborate/ — X-Content-Type-Options, HSTS, CSP
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — HSTS, CSP, X-Content-Type-Options
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — HSTS, CSP, X-Content-Type-Options

notice target=_blank link without rel=noopener (tab-napping)

Rule security.unsafe_cross_origin_links · Security · 50 occurrence(s)

https://epsilogen.com/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/2-million-raised-from-epidarex-capital/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/aacr-virtual-annual-meeting/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/epsilogen-licences-mov18-ige/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/genetic-engineering-news-article/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/igem-announces-funding-ige-antibody/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/iontas-and-igem-collaborate/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ — 3 external link(s) use target="_blank" without rel="noopener" — the opened page can hijack your tab (reverse tab-napping). Add rel="noopener noreferrer".

notice URL is very long

Rule url.too_long · URL · 9 occurrence(s)

Pages (showing 50 of 50)

URL	Status	Indexable	Words	In-links
https://epsilogen.com/ Home - Epsilogen	200	yes	637	50
https://epsilogen.com/arpa-h-backs-advancement-of-engineered-iga-antibody-therapeutics-toward-clinical-development/ ARPA-H Backs Advancement of Engineered IgA Antibody Therapeutics Toward Clinical Development - Epsilogen	200	yes	348	1
https://epsilogen.com/elucidating-the-relationship-between-affinity-and-potency-in-the-performance-of-therapeutic-ige/ HER2 affinity maturation: IgE antibodies exert strong immunostimulatory effects and their anti-tumour effectiveness is currently being assessed in clinical trials. - Epsilogen	200	yes	423	1
https://epsilogen.com/epsilogen-announces-the-appointment-of-cristina-oliva-md-phd-as-chief-medical-officer/ Epsilogen Announces the Appointment of Cristina Oliva, MD, PhD as Chief Medical Officer - Epsilogen	200	yes	684	1
https://epsilogen.com/board-of-directors/ Board of Directors - Epsilogen	200	yes	955	1
https://epsilogen.com/management-team/ Management Team - Epsilogen	200	yes	1051	1
https://epsilogen.com/2-million-raised-from-epidarex-capital/ £2 million raised from Epidarex Capital - Epsilogen	200	yes	782	0
https://epsilogen.com/2023-cancer-research-highlights-drug-development-at-its-best/ 2023 cancer research highlights: Drug development at its best - Epsilogen	200	yes	291	0
https://epsilogen.com/aacr-virtual-annual-meeting/ Encouraging interim data from a phase 1 clinical study evaluating MOv18 IgE in cancer patients with advanced solid tumours presented at the AACR Virtual Annual Meeting - Epsilogen	200	yes	1571	0
https://epsilogen.com/anti-cancer-pro-inflammatory-effects-of-an-ige-antibody-targeting-the-melanomaassociated-antigen-chondroitin-sulfate-proteoglycan-4/ Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanomaassociated antigen chondroitin sulfate proteoglycan 4 - Epsilogen	200	yes	273	0
https://epsilogen.com/apply-for-a-job/ Apply for a Job - Epsilogen	200	yes	289	0
https://epsilogen.com/biocentury/ BioCentury - Epsilogen	200	yes	263	0
https://epsilogen.com/episologen-lonza-manufacture-first-ige-to-treat-ovarian-cancer/ Epsilogen, Lonza manufacture first IgE to treat ovarian cancer - Epsilogen	200	yes	271	0
https://epsilogen.com/epsilogen-acquires-tigatx-to-expand-its-antibody-arsenal/ Epsilogen Acquires TigaTx to Expand its Antibody Arsenal - Epsilogen	200	yes	595	0
https://epsilogen.com/epsilogen-and-lonza-announce-successful-large-scale-gmp-manufacturing-of-mov18-an-ige-antibody-targeting-ovarian-cancer/ Epsilogen and Lonza Announce Successful Large-Scale GMP Manufacturing of MOv18, an IgE Antibody Targeting Ovarian Cancer - Epsilogen	200	yes	814	0
https://epsilogen.com/epsilogen-announces-acquisition-of-tigatx-inc-to-create-worlds-leading-pan-isotype-cancer-antibody-company/ Epsilogen Announces Acquisition of TigaTx, Inc. to Create World’s Leading Pan-Isotype Cancer Antibody Company - Epsilogen	200	yes	1385	0
https://epsilogen.com/epsilogen-announces-completion-of-oversubscribed-30-75-million-41-20-million-series-b-financing/ Epsilogen announces completion of oversubscribed £30.75 million ($41.20 million) Series B financing - Epsilogen	200	yes	1341	0
https://epsilogen.com/epsilogen-announces-cta-approval-for-phase-ib-trial-of-mov18-ige-in-platinum-resistant-ovarian-cancer/ Epsilogen announces CTA approval for Phase Ib trial of MOv18 IgE in platinum-resistant ovarian cancer - Epsilogen	200	yes	808	0
https://epsilogen.com/epsilogen-announces-formation-clinical-advisory-board/ Epsilogen Announces Formation of Clinical Advisory Board - Epsilogen	200	yes	905	0
https://epsilogen.com/epsilogen-announces-further-uk-government-funding/ Epsilogen announces further UK government funding for further development of a novel IgE antibody cancer immunotherapeutic - Epsilogen	200	yes	876	0
https://epsilogen.com/epsilogen-announces-initiation-of-phase-ib-trial-of-mov18-ige/ Epsilogen announces initiation of Phase Ib trial of MOv18 IgE - Epsilogen	200	yes	740	0
https://epsilogen.com/epsilogen-announces-significant-expansion-of-management-team-with-three-new-senior-hires/ Epsilogen announces significant expansion of management team with three new senior hires - Epsilogen	200	yes	894	0
https://epsilogen.com/epsilogen-announces-successful-completion-of-first-ever-clinical-trial-of-an-ige-antibody-phase-i-data-for-mov18-ige-demonstrates-potential-of-ige-therapy-in-cancer/ Epsilogen announces successful completion of first ever clinical trial of an IgE antibody; phase I data for MOv18 IgE demonstrates potential of IgE therapy in cancer - Epsilogen	200	yes	896	0
https://epsilogen.com/epsilogen-completes-12-5-million-series-b-financing-expansion/ Epsilogen completes £12.5 million Series B financing expansion - Epsilogen	200	yes	838	0
https://epsilogen.com/epsilogen-licences-mov18-ige/ Epsilogen licences MOv18 IgE, an anti-folate receptor alpha IgE antibody from King’s College London - Epsilogen	200	yes	804	0
https://epsilogen.com/epsilogen-raises-30m-series-b-bioworld/ Epsilogen raises £30.8M series B to support testing IgE antibody against ovarian cancer \| BioWorld - Epsilogen	200	yes	268	0
https://epsilogen.com/epsilogens-ceo-speaks-lu-rahman/ Epsilogen’s CEO speaks to Lu Rahman about their ongoing work in developing novel IgE antibodies to treat cancer. - Epsilogen	200	yes	275	0
https://epsilogen.com/esgo-2025-mov18-eposter/ ESGO 2025 MOv18 ePoster - Epsilogen	200	yes	243	0
https://epsilogen.com/genetic-engineering-news-article/ Genetic Engineering News Article - Epsilogen	200	yes	272	0
https://epsilogen.com/her2-ige/ HER2 IgE - Epsilogen	200	yes	452	0
https://epsilogen.com/how-cruks-biotech-like-group-is-accelerating-clinical-development-for-industry-partners/ How CRUK’s biotech-like group is accelerating clinical development for industry partners - Epsilogen	200	yes	289	0
https://epsilogen.com/igees/ IgEEs? - Epsilogen	200	yes	451	0
https://epsilogen.com/igem-announces-funding-ige-antibody/ IGEM Therapeutics announces UK government funding to develop a novel IgE antibody targeting solid tumours - Epsilogen	200	yes	641	0
https://epsilogen.com/igem-therapeutics-announces-final-close-of-5-million-series-a-financing-round/ IGEM Therapeutics announces final close of £5 million Series A financing round - Epsilogen	200	yes	1243	0
https://epsilogen.com/igem-therapeutics-announces-further-uk-government-funding/ IGEM Therapeutics announces further UK government funding to develop novel IgE antibody targeting solid tumours expressing HER2 - Epsilogen	200	yes	725	0
https://epsilogen.com/igem-therapeutics-announces-uk-government-funding-develop-novel-ige-antibody-targeting-solid-tumours/ IGEM Therapeutics shortlisted as a finalist in the “Best Start-up Biotech Company” - Epsilogen	200	yes	474	0
https://epsilogen.com/igem-therapeutics-appoints-dr-david-chiswell-non-executive-chairman/ IGEM Therapeutics appoints Dr David Chiswell as a Non-Executive Chairman - Epsilogen	200	yes	699	0
https://epsilogen.com/igem-therapeutics-awarded-best-start-biotech-company-2018-obn-awards/ IGEM Therapeutics awarded “Best Start-up Biotech Company” at the 2018 OBN Awards - Epsilogen	200	yes	545	0
https://epsilogen.com/igem-therapeutics-pursuing-novel-ige-antibodies-for-solid-tumors/ IGEM Therapeutics: Pursuing Novel IgE Antibodies For Solid Tumors - Epsilogen	200	yes	288	0
https://epsilogen.com/interim-phase-1-data-evaluating-mov18-ige/ Interim phase 1 data evaluating MOv18 IgE, an anti-folate receptor alpha IgE antibody, in cancer patients with advanced solid tumours to be presented at the AACR Virtual Annual Meeting - Epsilogen	200	yes	1192	0
https://epsilogen.com/iontas-and-igem-collaborate/ IONTAS and Epsilogen collaborate to identify novel IgE antibodies for cancer targets - Epsilogen	200	yes	708	0
https://epsilogen.com/key-opinion-leader-webinar-on-ige-antibodies-to-treat-cancer/ Key Opinion Leader Webinar on IgE Antibodies to Treat Cancer - Epsilogen	200	yes	306	0
https://epsilogen.com/mov18-opening-a-new-front-for-immunotherapy/ MOv18 – opening a new front for immunotherapy - Epsilogen	200	yes	301	0
https://epsilogen.com/nature-highlights-ige-cancer-antibodies-as-a-promising-new-technology-to-watch-in-2021/ Nature highlights IgE cancer antibodies as a promising new technology to watch in 2021. - Epsilogen	200	yes	274	0
https://epsilogen.com/novartis-backs-epsilogens-bid-turn-cinderella-antibody-new-class-cancer-drug-fierce-biotech/ Novartis backs Epsilogen's bid to turn 'Cinderella antibody' into new class of cancer drug \| Fierce Biotech - Epsilogen	200	yes	269	0
https://epsilogen.com/safety-and-anti-tumour-activity-of-the-ige-antibody-mov18-in-patients-with-advanced-solid-tumours-expressing-folate-receptor-alpha-a-phase-i-trial/ Safety and anti-tumour activity of the IgE antibody MOv18 in patients with advanced solid tumours expressing folate receptor-alpha: a phase I trial - Epsilogen	200	yes	287	0
https://epsilogen.com/scientific-founder/ Scientific Founder - Epsilogen	200	yes	353	0
https://epsilogen.com/the-life-sciences-future50/ The Life Sciences Future50 - Epsilogen	200	yes	288	0
https://epsilogen.com/uk-government-funding-for-antibody-treatments-for-ovarian-cancer/ Epsilogen announces further UK government funding to develop next generation antibody treatments for ovarian cancer - Epsilogen	200	yes	639	0
https://epsilogen.com/webinar-ige-antibodies-treat-cancer/ Epsilogen to Host Key Opinion Leader Webinar on IgE Antibodies to Treat Cancer - Epsilogen	200	yes	852	0

Audit your own site — free

157 checks, internal PageRank, render-diff. No signup, results in ~30s.

Scan your site →